 | • レポートコード：MRC2303I0223 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の動物向け医薬品有効成分（API）製造市場規模が、予測期間中に年平均7.1%で成長すると予測しています。本書では、動物向け医薬品有効成分（API）製造の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（抗寄生虫薬、抗感染薬、ワクチン、NSAIDs、その他）分析、合成種類別（化学ベースAPI、生物学的API、高効能API（HPAPI））分析、サービス種類別（インハウス、外部委託、受託開発、受託製造）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Sequent Scientific Ltd. （Alivira Animal Health Limited）、Stanley Black & Decker （Excel Industries Limited）、Ofichem Group、Menadiona、SUANFARMA、NGL Fine-Chem Ltd.、FIS - Fabbrica Italiana Sintetici S.p.A.、Sidhiv Pharma 、Grupo Indukern S.L.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の動物向け医薬品有効成分（API）製造市場規模：製品別 - 抗寄生虫薬の市場規模 - 抗感染薬の市場規模 - ワクチンの市場規模 - NSAIDsの市場規模 - その他製品の市場規模 ・世界の動物向け医薬品有効成分（API）製造市場規模：合成種類別 - 化学ベースAPIの市場規模 - 生物学的APIの市場規模 - 高効能API（HPAPI）の市場規模 ・世界の動物向け医薬品有効成分（API）製造市場規模：サービス種類別 - インハウス製造における市場規模 - 外部委託における市場規模 - 受託開発における市場規模 - 受託製造における市場規模 ・世界の動物向け医薬品有効成分（API）製造市場規模：地域別 - 北米の動物向け医薬品有効成分（API）製造市場規模 アメリカの動物向け医薬品有効成分（API）製造市場規模 カナダの動物向け医薬品有効成分（API）製造市場規模 メキシコの動物向け医薬品有効成分（API）製造市場規模 … - ヨーロッパの動物向け医薬品有効成分（API）製造市場規模 ドイツの動物向け医薬品有効成分（API）製造市場規模 イギリスの動物向け医薬品有効成分（API）製造市場規模 フランスの動物向け医薬品有効成分（API）製造市場規模 … - アジア太平洋の動物向け医薬品有効成分（API）製造市場規模 中国の動物向け医薬品有効成分（API）製造市場規模 インドの動物向け医薬品有効成分（API）製造市場規模 日本の動物向け医薬品有効成分（API）製造市場規模 … - 中東・アフリカの動物向け医薬品有効成分（API）製造市場規模 GCC諸国の動物向け医薬品有効成分（API）製造市場規模 南アフリカの動物向け医薬品有効成分（API）製造市場規模 … - 南米の動物向け医薬品有効成分（API）製造市場規模 ブラジルの動物向け医薬品有効成分（API）製造市場規模 アルゼンチンの動物向け医薬品有効成分（API）製造市場規模 … - その他地域の動物向け医薬品有効成分（API）製造市場規模 ・競争状況 ・市場機会・将来の動向 |
The Veterinary Active Pharmaceutical Ingredients Manufacturing Market is expected to register a CAGR of 7.1% over the forecast period.
The COVID-19 epidemic has had a significant impact on the market. Several animals, including cats, gorillas, dogs, farmed mink, otters, and others, were infected with the virus, which resulted in an increased risk of viral spread among domesticated animals, in turn boosting the demand for veterinary drugs. However, amid the pandemic, the prices of some veterinary APIs and feed additives rose sharply. According to a publication by Hangzhou DE Mark Industrial Co. Ltd., a manufacturer of veterinary pharmaceutical raw materials and specialty feed additives, in January 2022, the price of vitamin C grew dramatically, reaching roughly 30 RMB (USD 4.19) per kg, an almost 50% increase. While the cost of Vitamin D3 nearly doubled. Thus, such an increase associated with the prices of veterinary manufacturing products adversely impacted the market’s growth during the pandemic. However, increasing incidences of COVID-19 among animals have surged the demand for several drugs to combat the SARS-CoV-2 virus, which is anticipated to have a positive impact on the market’s growth. For instance, as per CDC and NCEZID data published in March 2022, more than 200 pets, including dogs, ferrets, and cats, were infected by the SARS-CoV-2 virus in the United States. Therefore, as per the analysis, such incidences are projected to augment market growth over the coming years.
The factors expected to drive the market growth include the increasing prevalence of zoonotic diseases, increasing animal populations and pet ownership, and rising numbers of veterinarians and veterinary visits. The market is highly propelled by the elevated prevalence of zoonotic diseases. Since human-animal connections are necessary for existence, this makes zoonoses easier to spread. Human-animal cohabitation is more common in poorer nations, particularly among rural populations. This inextricable relationship is evidenced by the higher occurrence of zoonoses in underdeveloped countries.
For instance, the Indian Journal of Medical Research in 2021 stated that animals are responsible for 70% of emerging infectious diseases; every year, five new diseases are generated, three of which are of animal origin, and zoonotic infections account for 80% of agents with potential bioterrorism use. In May 2022, the USDA Animal and Plant Health Inspection Service (APHIS) and the New Jersey Department of Agriculture (NJDA) confirmed New Jersey’s first highly pathogenic avian influenza case in a Monmouth County non-commercial backyard poultry flock. As a result of the increasing prevalence of infectious diseases, there is a greater need for effective treatment options, which increases the demand for active pharmaceutical ingredient manufacturing and supports market growth.
Moreover, the increasing pet population and pet adoption are expected to propel the market’s growth. For instance, according to the People’s Dispensary for Sick Animals (PDSA) PAW Report 2021, there were 9.6 million pet dogs, 10.7 million pet cats, and 900,000 pet rabbits in the United Kingdom. The same source also reported 2 million pets being adopted since March 2020 in the United Kingdom. The pet population is susceptible to several diseases, and thus, increased adoption of this population is expected to raise demand for veterinary drugs, ultimately boosting the market’s growth.
Various strategies adopted by the key market players, such as product launches, mergers, and acquisitions, are expected to boost the market over the forecast period. For instance, in November 2021, ArchiMed acquired the majority of its stake in Madrid-based SuanPharma, a provider of veterinary active pharmaceutical ingredients. The goal was to finance ambitious industrial consolidation and organic expansion to position it as a leader in the API industry.
Thus, all the above-mentioned factors, such as the growing prevalence of zoonotic diseases and the rising adoption of animals, are expected to boost market growth over the forecast period. However, lack of awareness and the high cost of animal care coupled with stringent regulations may restrain the market over the forecast period.
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Trends
The Vaccines Segment is Expected to Hold a Significant Market Share in the Veterinary Active Pharmaceutical Ingredients Manufacturing Market
The vaccine segment is expected to hold a significant market share in the veterinary active pharmaceutical ingredients manufacturing market.
The increased need for vaccines due to the high frequency of chronic diseases in animals is credited to the segment’s growth. Furthermore, rising livestock populations and animal husbandry, as well as the commercialization of animal products, are likely to raise vaccine demand, propelling segment growth forward. Rabies vaccinations, equine influenza virus vaccines, and foot-and-mouth disease vaccines are the most commonly used animal vaccines, which inhibit the transfer of infectious pathogens by replicating naturally acquired immunity.
According to the study published in Infection Ecology & Epidemiology in September 2021, one of the most dangerous zoonotic diseases in the world is salmonellosis. Salmonella prevalence in animals and risk factors for increased transmission of Salmonella spp. from animals to people were evident. In Spain, the prevalence of salmonella in dogs accounted for 1.85%. In China, 243 dogs were found to have a slightly higher prevalence of salmonella at 9.47%. Salmonellosis is effectively treated with vaccines, and the rising prevalence of salmonellosis is expected to increase demand for vaccines, thereby boosting the segment’s growth.
Furthermore, the establishment of an animal vaccine manufacturing plant to fulfill the global need for veterinary drugs tends to increase API demand to make the finished product that successfully treats animal diseases. For instance, in October 2022, Indian Immunologicals Ltd. (IIL) announced an INR 700 crore (USD 85.6 million) investment in Genome Valley, Hyderabad, to establish a new animal vaccine manufacturing facility.
The constant development of technologically superior vaccines, as well as the spread of diseases, have all contributed to changing market dynamics, thereby augmenting the segment’s growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the veterinary active pharmaceutical ingredients manufacturing market. Zoonoses pose a concern for human health since animals are frequently the natural source of disease. The rising frequency of zoonotic diseases is a major factor driving market expansion in the region.
According to the 2021-2022 National Pet Owners Survey, conducted by the American Pet Products Association (APPA), around 70% of United States households own a pet, which equates to 90.5 million homes, including 45.3 million cats and 69 million dogs. The same source also reports that the annual expenditure on a routine visit for dogs accounts for USD 242, whereas it is USD 178 for cats in the country. Moreover, factors such as a rise in R&D investments, advancements in procedures, increased consumption of meat, and mandatory vaccination is anticipated to boost market growth during the forecast period.
An article by the Mainstreet Animal Hospital in Canada on Primary Veterinary Care in March 2022 discussed the various complications faced by pets and their management. The article indicated that old age is a major factor contributing to the onset of various chronic diseases such as osteoarthritis, heart issues, kidney issues, endocrinological problems, etc. The rise in the number of chronic diseases in veterinary animals and the requirement for proper medical management, such as providing effective medications for affected animals, is likely to propel the growth of the studied market in the region.
Thus, all the above-mentioned factors, such as rising pet adoption and the growing burden of chronic disease in animals, are expected to boost the market in the region over the forecast period.
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Competitor Analysis
The veterinary active pharmaceutical ingredients manufacturing market is consolidated and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies that are currently dominating the market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group, Menadiona, SUANFARMA, NGL Fine-Chem Ltd., FIS (Fabbrica Italiana Sintetici S.p.A.), Zoetis, Indukern, Huvepharma, and Ourofino.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Zoonotic Diseases
4.2.2 Increasing Animal Population And Pet Ownership
4.2.3 Rising Number of Veterinarians and Veterinary Visits
4.3 Market Restraints
4.3.1 Lack of Awareness and High Cost of Animal Care
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Antiparasitic
5.1.2 Anti-infectives
5.1.3 Vaccines
5.1.4 NSAIDs
5.1.5 Others
5.2 By Synthesis Type
5.2.1 Chemical Based API
5.2.2 Biological API
5.2.3 Highly Potent API (HPAPI)
5.3 By Service Type
5.3.1 In House
5.3.2 Contract Outsourcing
5.3.2.1 Contract Development
5.3.2.2 Contract Manufacturing
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Sequent Scientific Ltd. (Alivira Animal Health Limited)
6.1.2 Stanley Black & Decker (Excel Industries Limited)
6.1.3 Ofichem Group
6.1.4 Menadiona
6.1.5 SUANFARMA
6.1.6 NGL Fine-Chem Ltd.
6.1.7 FIS – Fabbrica Italiana Sintetici S.p.A.
6.1.8 Sidhiv Pharma
6.1.9 Grupo Indukern S.L.
6.1.10 Chempro Pharma Private Limited
6.1.11 AMGIS Lifescience Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS